KELISIA MCKAY: Open Payments
NPI 1962447045 · KENNER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$246 in 12 payments from 8 companies in 2025. Trend: 2023 $1,267 · 2024 $1,409 · 2025 $246
Food & beverage: $246
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $86 |
| E.R. Squibb & Sons, L.L.C. | 1 | $43 |
| ABBVIE INC. | 2 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| Cipher Pharmaceuticals US LLC | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
Products named: COBENFY, VRAYLAR, INGREZZA, REXULTI, XIFAXAN, Natroba, Auvelity.
Industry payments across LA — which companies pay providers there.
